The Chinese treatment market for colorectal cancer (CRC) will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 15.1%.
Reportstack’s latest report states that this increase, which will make China the third largest global market for CRC treatment behind the US and Japan, will be driven by increasing disease incidence in urban populations, rising numbers of people covered by private health insurance and improved access to branded biologicals.
One of GlobalData’s Analyst covering Oncology and Hematology, says that growth will be stymied by the patent expiration of Avastin, the leading drug in the Chinese CRC treatment market, and the slower uptake of pipeline therapies.
To access full report with TOC, please visit PharmaPoint: Colorectal Cancer-Global Drug Forecast and Market Analysis to 2023.
“There is often a delay in new drug launches in China relative to the US, Europe and Japan, due to an extended approval process by the China Food and Drug Administration (CFDA). For drugs that have not undergone clinical trials in Chinese patients prior to their application submission, the CFDA can require additional safety studies to be conducted in China before accepting a registration application.
“As nintedanib, Cyramza, and Imprime PGG are examples of pipeline products that have not undergone clinical trials in China, we do not expect them to launch in this market during the forecast period.”
Despite this, it was predicted that the market entry of four additional drugs by 2023. These include Amgen/Takeda’s Vectibix, Bayer’s Stivarga, Sanofi’s Zaltrap, and Taiho Pharmaceutical’s Lonsurf.
“These agents will garner combined revenues of $334 million in 2023, representing 32% of the Chinese CRC treatment market.
“Stivarga is expected to be the clear market leader of these drugs, with peak-year sales of $291 million expected in 2023. This will follow its label extension as an adjuvant treatment for CRC patients with resected liver metastases and prior chemotherapy neoadjuvant/adjuvant treatment,”.
About Reportstack:
Reportstack is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack members with cutting edge research products to facilitate strategic business decisions.
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
No comments:
Post a Comment